Bridging the gap between innovation and capital
Daiichi Sankyo
Focus on early-stage biotech companies
Program
Daiichi Sankyo is an innovative global healthcare company that contributes to the sustainable development of society by discovering, developing and delivering new standards of care to enrich quality of life around the world.
OPPORTUNITY
LaunchBio, Citrin Cooperman, and Silicon Valley Bank, a Division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with Daiichi Sankyo.
Since 1899, Daiichi Sankyo has leveraged its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need.
Applications will be selected based on meeting the following criteria:
Geography
Open to investments anywhere in the USA and North America
Company Type
Companies seeking funding for Pre-Seed and Seed
Stage
Companies seeking funding for Pre-Seed, Seed, and Series A
Strategic Interests
Oncology: ADC/TCE therapeutic index expansion; tumor-specific binders & discovery methods; next-gen targeted protein degradation; tumor-specific delivery tech
Non-Oncology: Immune diseases, non-Type 2 COPD, Dry AMD, Retinitis pigmentosa, Alzheimer’s, CV/Metabolic gene therapy, organ/cell-specific delivery
Cross-TA: AI/ML target discovery (CVM, Inflammation, Oncology); in vivo direct reprogramming (beta cell, cardiomyocyte, neuron, rejuvenation)
Modalities of Interest
- Small molecules
- Biologics
- Protein-based therapeutics
- RNA-based therapeutics
- Gene therapies
- Regenerative medicine & tissue engineering
- Oncolytic viruses
Preferred Therapeutic Areas
- Cardiology
- Immunology
- Neurology
- Oncology
- Opthamology
- Pulmonology
Positioning Preference
First-in-Class, Best-in-Class, Platform-Enabled Modality Innovation; common/large-population indications
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Citrin Cooperman and Silicon Valley Bank, a division of First Citizens Bank.